Payment overview · 2025
General Payments
$587.08
30 reported records · 7 companies
Healthcare provider profile · identity verified
Daniel Richard Lenoir, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OAK RIDGE, TN · NPI 1861474967
Verified facts
What the public records show
CMS Open Payments records show Daniel Richard Lenoir, M.D. received $587.08 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $255.29 | 43.5% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.88 | 27.4% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.77 | 9.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.32 | 7.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.00 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.41 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.41 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.08 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $255.29 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $193.18 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.96 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.77 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.57 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 139 |
| Gabapentin | Gabapentin | 496 | 85 |
| Lisinopril | Lisinopril | 436 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 380 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 52 |
| Prednisone | Prednisone | 271 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 89 |
| Celecoxib | Celecoxib | 255 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 52 |
| Metformin Hcl | Metformin Hcl | 253 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 253 | 46 |
| Potassium Chloride | Potassium Chloride | 252 | 83 |
| Furosemide | Furosemide | 243 | 89 |
| Eliquis | Apixaban | 242 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 242 | 31 |
| Omeprazole | Omeprazole | 236 | 77 |
| Alprazolam | Alprazolam | 233 | 46 |
| Simvastatin | Simvastatin | 225 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 216 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 191 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 190 | 53 |
| Glimepiride | Glimepiride | 185 | 49 |
| Ozempic | Semaglutide | 185 | 31 |
| Famotidine | Famotidine | 166 | 52 |
| Trazodone Hcl | Trazodone Hcl | 165 | 51 |
| Carvedilol | Carvedilol | 160 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 157 | 22 |
| Allopurinol | Allopurinol | 153 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 151 | 39 |
| Sertraline Hcl | Sertraline Hcl | 151 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 147 | 33 |
| Donepezil Hcl | Donepezil Hcl | 146 | 41 |
| Telmisartan | Telmisartan | 142 | 39 |
| Meloxicam | Meloxicam | 140 | 40 |
| Losartan Potassium | Losartan Potassium | 132 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 130 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 128 | 37 |
| Lorazepam | Lorazepam | 125 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 27 |
| Montelukast Sodium | Montelukast Sodium | 117 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 31 |
| Ramipril | Ramipril | 117 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 33 |
| Clonazepam | Clonazepam | 115 | 18 |
| Ezetimibe | Ezetimibe | 112 | 34 |
| Bumetanide | Bumetanide | 111 | 32 |
| Synthroid | Levothyroxine Sodium | 110 | 30 |
| Cefdinir | Cefdinir | 108 | 84 |
| Tramadol Hcl | Tramadol Hcl | 108 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 52 |
| Pregabalin | Pregabalin | 102 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 38 |
| Jardiance | Empagliflozin | 100 | 22 |
| Promethazine Hcl | Promethazine Hcl | 99 | 25 |
| Methocarbamol | Methocarbamol | 98 | 33 |
| Bupropion Xl | Bupropion Hcl | 96 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 30 |
| Humalog Kwikpen U-100 | Insulin Lispro | 91 | 24 |
| Ibuprofen | Ibuprofen | 89 | 23 |
| Mirtazapine | Mirtazapine | 85 | 17 |
| Mounjaro | Tirzepatide | 84 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 84 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 26 |
| Nortriptyline Hcl | Nortriptyline Hcl | 74 | 15 |
| Spironolactone | Spironolactone | 74 | 23 |
| Finasteride | Finasteride | 73 | 19 |
| Warfarin Sodium | Warfarin Sodium | 72 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 13 |
| Trulicity | Dulaglutide | 71 | 12 |
| Benazepril Hcl | Benazepril Hcl | 70 | 21 |
| Buspirone Hcl | Buspirone Hcl | 67 | 19 |
| Ondansetron Odt | Ondansetron | 67 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 67 | 20 |
| Farxiga | Dapagliflozin Propanediol | 66 | 14 |
| Levetiracetam | Levetiracetam | 65 | 11 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 19 |
| Naproxen | Naproxen | 59 | 17 |
| Azithromycin | Azithromycin | 58 | 48 |
| Morphine Sulfate Er | Morphine Sulfate | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 16 |
| Meclizine Hcl | Meclizine Hcl | 56 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 16 |
| Levofloxacin | Levofloxacin | 54 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 48 |
| Sucralfate | Sucralfate | 52 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 44 |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | 13 |
| Atenolol | Atenolol | 47 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Lamotrigine | Lamotrigine | 47 | 11 |
| Testosterone | Testosterone | 47 | 14 |
| Doxepin Hcl | Doxepin Hcl | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Lovastatin | Lovastatin | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 41 | 19 |
| Nystatin | Nystatin | 41 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 12 |
| Topiramate | Topiramate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Nitroglycerin | Nitroglycerin | 38 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Dexamethasone | Dexamethasone | 36 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Linzess | Linaclotide | 32 | 11 |
| Nabumetone | Nabumetone | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Amoxicillin | Amoxicillin | 30 | 22 |
| Emgality Pen | Galcanezumab-Gnlm | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 13 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Glyburide | Glyburide | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 12 |
| Methimazole | Methimazole | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Humulin R | Insulin Regular, Human | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Temazepam | Temazepam | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Armodafinil | Armodafinil | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 11 |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.08 · 30 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, ENHERTU, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error